These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35089113)

  • 81. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.
    Masotti L; Landini G; Panigada G; Grifoni E; Tarquini R; Cei F; Cimolato BMA; Vannucchi V; Di Pietro M; Piani F; Fortini A; Faraone A; Nenci G; Cipollini F; Blanc P; Lotti P; Di Natale M; Risaliti F; Aquilini D; Seravalle C; Bribani A; Farsi A; Micheletti I; Cioni E; Pelagalli G; Mattaliano C; Pinto G; Madonia EM; Sivieri I; Mannini M; Valoriani A; Brancati S; Rosselli M; Pavone E; Burla MC; Sergi A;
    Int Immunopharmacol; 2022 Jun; 107():108709. PubMed ID: 35334359
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.
    Kenny G; Mallon PWG
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1279-1287. PubMed ID: 34187281
    [No Abstract]   [Full Text] [Related]  

  • 84. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
    Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
    Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19).
    Maslennikov R; Ivashkin V; Vasilieva E; Chipurik M; Semikova P; Semenets V; Russkova T; Levshina A; Grigoriadis D; Magomedov S; Efremova I; Dzhakhaya N
    Eur Cytokine Netw; 2021 Mar; 32(1):8-14. PubMed ID: 34346869
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Does timing of tocilizumab administration affect mortality in COVID-19? A Scottish multicentre retrospective cohort study.
    MacGregor F; Oprey A; Caulfield C; MacTavish P; Lowrie R; Henderson P
    BMJ Open Respir Res; 2024 Aug; 11(1):. PubMed ID: 39214629
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis.
    Gorham J; Moreau A; Corazza F; Peluso L; Ponthieux F; Talamonti M; Izzi A; Nagant C; Ndieugnou Djangang N; Garufi A; Creteur J; Taccone FS
    PLoS One; 2020; 15(12):e0244628. PubMed ID: 33382773
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    ; Gordon AC; Mouncey PR; Al-Beidh F; Rowan KM; Nichol AD; Arabi YM; Annane D; Beane A; van Bentum-Puijk W; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buzgau A; Cheng AC; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Lamontagne F; Lawler PR; Leavis HL; Linstrum KM; Litton E; Lorenzi E; Marshall JC; Mayr FB; McAuley DF; McGlothlin A; McGuinness SP; McVerry BJ; Montgomery SK; Morpeth SC; Murthy S; Orr K; Parke RL; Parker JC; Patanwala AE; Pettilä V; Rademaker E; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Sligl WI; Turgeon AF; Turner AM; van de Veerdonk FL; Zarychanski R; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Webb SA; Derde LPG
    N Engl J Med; 2021 Apr; 384(16):1491-1502. PubMed ID: 33631065
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.
    Berlot G; Pintacuda S; Moro E; Paluzzano G; Scamperle A; Chillemi A; Longo I; Dattola R; Roman-Pognuz E; Tomasini A
    Int J Artif Organs; 2022 Jan; 45(1):75-80. PubMed ID: 33573449
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
    Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L
    Immunol Lett; 2020 Dec; 228():122-128. PubMed ID: 33161002
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.
    Fernández-Ruiz M; López-Medrano F; Carretero O; Parra P; Ruiz-Merlo T; Aguado JM;
    Med Clin (Barc); 2022 Jun; 158(12):608-612. PubMed ID: 34243954
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.
    Pettit NN; Nguyen CT; Mutlu GM; Wu D; Kimmig L; Pitrak D; Pursell K
    J Med Virol; 2021 Mar; 93(3):1459-1464. PubMed ID: 32790075
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.
    Somers EC; Eschenauer GA; Troost JP; Golob JL; Gandhi TN; Wang L; Zhou N; Petty LA; Baang JH; Dillman NO; Frame D; Gregg KS; Kaul DR; Nagel J; Patel TS; Zhou S; Lauring AS; Hanauer DA; Martin E; Sharma P; Fung CM; Pogue JM
    Clin Infect Dis; 2021 Jul; 73(2):e445-e454. PubMed ID: 32651997
    [TBL] [Abstract][Full Text] [Related]  

  • 94. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19.
    Guirao JJ; Cabrera CM; Jiménez N; Rincón L; Urra JM
    Mol Immunol; 2020 Dec; 128():64-68. PubMed ID: 33075636
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
    Mella A; Mingozzi S; Gallo E; Lavacca A; Rossetti M; Clari R; Randone O; Maffei S; Salomone M; Imperiale D; Biancone L
    Transpl Infect Dis; 2020 Dec; 22(6):e13348. PubMed ID: 32500936
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia.
    Górgolas Hernández-Mora M; Cabello Úbeda A; Prieto-Pérez L; Villar Álvarez F; Álvarez Álvarez B; Rodríguez Nieto MJ; Carrillo Acosta I; Fernández Ormaechea I; Al-Hayani AWM; Carballosa P; Calpena Martínez S; Ezzine F; Castellanos González M; Naya A; López De Las Heras M; Rodríguez Guzmán MJ; Cordero Guijarro A; Broncano Lavado A; Macías Valcayo A; Martín García M; Bécares Martínez J; Fernández Roblas R; Piris Pinilla MÁ; Fortes Alen J; Sánchez Pernaute O; Romero Bueno F; Heili-Frades S; Peces-Barba Romero G
    Int J Infect Dis; 2021 Jan; 102():303-309. PubMed ID: 33115682
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers.
    Rubio-Rivas M; Mora-Luján JM; Montero A; Aguilar García JA; Méndez Bailón M; Fernández Cruz A; Oriol I; Teigell-Muñoz FJ; Dendariena Borque B; De la Peña Fernández A; Fernández González R; Gil Sánchez R; Fernández Fernández J; Catalán M; Cortés-Rodríguez B; Mella Pérez C; Montero Rivas L; Suárez Fuentetaja R; Ternero Vega JE; Ena J; Martin-Urda Díez-Canseco A; Pérez García C; Varona JF; Casas-Rojo JM; Millán Núñez-Cortés J;
    J Gen Intern Med; 2022 Jan; 37(1):168-175. PubMed ID: 34664188
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.
    Rashad A; Mousa S; Nafady-Hego H; Nafady A; Elgendy H
    Sci Rep; 2021 Apr; 11(1):8816. PubMed ID: 33893337
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
    Chamorro-de-Vega E; Rodriguez-Gonzalez CG; Manrique-Rodríguez S; Lobato-Matilla E; García-Moreno F; Olmedo M; Correa-Rocha R; Valerio M; Aldámiz-Echevarria T; Machado M; Sancho-Gonzalez M; Lopez-Bernaldo-de-Quirós JC; Ruiz-Briones P; Romero-Jiménez R; Sarobe-González C; Gimenez-Manzorro A; Collado-Borrell R; Fernandez-Llamazares CM; Revuelta-Herrero JL; Somoza-Fernandez B; Garcia-Sanchez S; Taladriz-Sender I; Bouza E; Herranz A; Muñoz P; Sanjurjo M
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):249-260. PubMed ID: 33499687
    [No Abstract]   [Full Text] [Related]  

  • 100. Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis.
    Cassone G; Dolci G; Besutti G; Braglia L; Pavone P; Corsini R; Sampaolesi F; Iotti V; Teopompi E; Massari M; Fontana M; Ghidoni G; Matei A; Croci S; Negri EA; Costantini M; Facciolongo N; Salvarani C
    PLoS One; 2022; 17(1):e0262908. PubMed ID: 35081151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.